Eevia Health Plc received a 159 KSEK / 14 KEUR sales order for a pine bark extract product
Eevia Health Plc’s (”Eevia” or ”The Company”) has received a 14 KEUR sales order from a US company for Fenoprolic® 70 Organic, an organically certified pine bark extract.
The customer is a medium-sized US contract manufacturer that manufactures consumer-ready dosage forms, such as tablets, lozenges, hard-gel capsules, and similar, for various brand holders across North America. The contract manufacturer also has its own brand. The end customer is a well-known brand that has a very strong position within organic and natural supplements in the US.
The sales value to Eevia of this new order is kEUR 14 and the product is in stock. The product is Eevia’s ingredient Fenoprolic® 70 Organic, which is a highly concentrated and organically certified pine bark extract with 70% oligomeric proanthocyanidins or OPCs as these are called in the industry.
“Although we were in contact some years ago, before Covid, we see this as the first order from this customer. Although the order is small, we are excited, because the contract manufacturer serves several large brands, and our pine bark extract has the potential to compete well. The customer is excited in general about our polyphenol products, and we expect further orders during 2024,” states Anna-Maija Vanhatalo, Sales Manager at Eevia Health.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia’s other raw materials, such as bilberry, lingonberry, chaga mushroom, and pine bark, are wild-harvested sustainably.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.
